drugset / Trial / NCT00267319

FOCUS Fatigue Outcome in Copaxone USers

NCT00267319

Phase 4 Completed 111 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

* The study primarily investigates the effect of copaxone on fatigue during treatment, compared to baseline in patients with relapsing-remitting multiple sclerosis. * Secondary outcome measures are:disability, relapse rate, quality of life and depression.

Timeline

Start
2003-06
Primary completion
2006-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Glatiramer Acetate Small molecule

Indications